PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

Pfizer's first-half 2025 top-line growth was propelled by strong non-COVID operational revenues, notably from new launches and acquired assets like Seagen, which contributed $4.7 billion and grew approximately 15% operationally year-over-year, effectively offsetting declining COVID product sales. The Seagen acquisition, expected to add over $10 billion in risk-adjusted revenues by 2030, is central to Pfizer's strategy to achieve an estimated 6% revenue CAGR from 2025-2030 and largely mitigate upcoming loss of exclusivity challenges. Despite a slight year-to-date stock decline, Pfizer's shares appear attractively valued relative to the industry and its historical average, with consensus earnings estimates recently increasing.

Analysis

Pfizer is successfully executing a strategic pivot from its pandemic-era reliance on COVID-19 products, demonstrating robust growth in its non-COVID portfolio. In the first half of 2025, newly launched and acquired products generated $4.7 billion in revenue, marking an approximate 15% operational increase year-over-year. The December 2023 acquisition of Seagen is central to this strategy, significantly bolstering the company's oncology franchise with four antibody-drug conjugates and contributing meaningfully to revenues. This growth trajectory is critical as Pfizer projects it will largely offset the upcoming 2026-2030 loss of exclusivity (LOE) cliff and support a forecasted revenue CAGR of approximately 6% through 2030. The Seagen assets alone are expected to contribute over $10 billion in risk-adjusted revenues by 2030. From a valuation perspective, Pfizer appears attractive; its stock trades at a forward P/E of 7.95, a discount to both its five-year mean of 10.79 and the industry average of 13.73. This is further supported by recent upward revisions in consensus earnings estimates for 2025 and 2026, signaling improving analyst sentiment despite the stock's modest 2.1% year-to-date decline.

Key Decisions for Investors

• Given the stock's forward P/E discount relative to its historical average and industry peers, coupled with recent upward earnings estimate revisions, investors may consider the current valuation an attractive entry point.
• Investors should closely monitor the quarterly revenue performance of the non-COVID portfolio, particularly the assets acquired from Seagen, to validate the company's ability to meet its projected 6% CAGR and offset the upcoming patent cliff.
• While Pfizer's oncology strategy is promising, it is crucial to track the competitive landscape, as strong growth from rivals like AstraZeneca, Merck, and Bristol-Myers could affect market share and pricing power for key products.
• Consider the stock's relative outperformance, declining just 2.1% YTD versus the industry's 6.4% fall, as an indicator of market confidence in its strategic transition away from COVID-related revenue.